An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival.

doi:10.1093/neuonc/noaf250

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival.

Neuro-oncology - 1 Jan 2026

Smith Kyle S, Dhanda Sandeep K, Billups Catherine A, Sioson Edgar, Lu Congyu, Peraza Airen Zaldivar, Gangwani Karishma, Li Yimei, Li Qian, Lin Tong, Michalski Jeff M, Packer Roger J, Olson James M, Leary Sarah E S, Fouladi Maryam, Gajjar Amar, Zhou Xin, Onar-Thomas Arzu, Northcott Paul A, Robinson Giles W

Abstract excerpt

BACKGROUND: The identification of clinical and molecular heterogeneity in medulloblastoma has produced risk-stratified therapy, but establishing the most effective yet least toxic regimens has remained elusive owing to numerous treatment options. To improve risk-stratification, we performed an integrated analysis from three clinical trials. METHODS: Medulloblastoma patients from ACNS0331/NCT00085735,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cerebellar Neoplasms

Share to Chemoradiotherapy

Share to Clinical Trials as Topic

Share to DNA Methylation

Share to Medulloblastoma

Share to Risk Assessment

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 41159377
DOI: 10.1093/neuonc/noaf250
PMCID: PMC12962632

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival.PMID 41159377Read ↗

Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03).Semantic proximity Read ↗

Long-term outcomes by clinical and molecular risk stratification in patients with medulloblastoma receiving risk-adapted therapy.Semantic proximity Read ↗

Identification of low and very high-risk patients with non-WNT/non-SHH medulloblastoma by improved clinico-molecular stratification of the HIT2000 and I-HIT-MED cohortsSemantic proximity Read ↗

Medulloblastoma: Molecular Classification-Based Personal Therapeutics.Semantic proximity Read ↗

Cytogenetic Prognostication Within Medulloblastoma SubgroupsSemantic proximity Read ↗

Subtyping of Group 3/4 medulloblastoma as a potential prognostic biomarker among patients treated with reduced dose of craniospinal irradiation: a Japanese Pediatric Molecular Neuro-Oncology Group studySemantic proximity Read ↗

In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patientsSemantic proximity Read ↗

A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma.Semantic proximity Read ↗

Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions.Semantic proximity Read ↗

Medulloblastoma in the Molecular EraSemantic proximity Read ↗

Tailoring Medulloblastoma Treatment Through Genomics: Making a Change, One Subgroup at a TimeSemantic proximity Read ↗

Molecular characterisation defines clinically-actionable heterogeneity within Group 4 medulloblastoma and improves disease risk-stratification.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.